Retatrutide is an experimental metabolic therapy designed to treat obesity and related metabolic disorders
Some people may feel full quickly, feel bloated after eating, or notice more burping than usual
11 Conclusion Glucagon-like peptide-1 receptor agonists are pivotal in managing T2DM and obesity, enhancing glycaemic control by boosting insulin secretion, reducing glucagon levels, delaying gastric emptying, and promoting satiety
Not everyone taking a GLP-1 medicine will experience the same benefits
If you believe you are experiencing a side effect related to any medicine, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS)